New drug development for known and emerging viruses / edited by Helga Rübsamen-Schaeff and Helmut Buschmann

ABOUT THE AUTHOR
Helga Rübsamen-Schaeff , PhD, is founding CEO of AiCuris and the chair of AiCuris' Scientific Advisory Board. Before founding AiCuris she served at Bayer as SVP and Head of Infectious Disease Research. Before that time, she was Scientific and Managing Director of the Georg-Speyer-Haus in Frankfurt. A chemist by training, Professor Rübsamen-Schaeff has been professor of biochemistry at the University of Frankfurt since 1988. Her research interests focus on research and development of antiviral drugs, novel resistance-breaking antibiotics, emerging infectious diseases and oncology. Prevymis, a drug against HCMV discovered under her direction has reached the market.
Helmut Buschmann, PhD, has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors in different therapeutic areas, from pain research to anti-infectives. Currently, he is Head of Chemistry, Pharmaceutical Development and Patent Affairs at AiCuris and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.

Includes bibliographical references and index

Disease Overview, Targets for Therapy and Open Issues / Christoph Stephan -- Curing Hepatitis C with Direct-Acting Antiviral Therapy / Michael J Sofia -- Antiviral Drugs Against Influenza Virus / Oliver Planz -- Respiratory Syncytial Virus Immunoreactivity, Vaccine Development, and Therapeutics / Farah Elawar, Matthias Gotte, Nelson Lee, Rachel Fearns, David J Marchant -- Herpes Simplex Viruses / Alexander Birkmann -- Antiviral Strategies Against the Human Cytomegalo Virus / Helga Rübsamen-Schaeff -- Antiviral Targeting of the Complex Epstein Barr Virus Life Cycle / Christian Münz -- Kaposi's Sarcoma-associated Herpesvirus-Antiviral Treatment / Thomas F Schulz -- Direct-Acting Antivirals for the Treatment of Chronic Hepatitis B Virus (HBV) Infection / Angelica Corcuera, Alastair Donald, Andreas Urban -- Hepatitis E Virus-Current Developments in Antiviral Strategies / Daniel Todt, Patrick Behrendt, Eike Steinmann -- Antiviral Therapy of Adenovirus Infections / Peter Lischka -- ssDNA-Viruses: Human Parvovirus Infection / Susanne Modrow -- Antiviral Targets and Strategies to Treat and Prevent Human Norovirus Infections / Jana Van Dycke, Arno Cuvry, Johan Neyts, Joana Rocha-Pereira -- Antiviral Strategies Against (Non-polio) Picornaviruses / Rana Abdelnabi, Jim Baggen, Carmen Mirabelli, Johan Neyts -- Novel Antiviral Strategies Against Emerging Arbovirus Infections / Yannick Brüggemann, Carina Elsner, Stephanie Pfaender -- Current Therapies for Biosafety Level 4 Pathogens / Lucie Fénéant*, Bianca Bodmer*, Thomas C Mettenleiter, Allison Groseth, Thomas Hoenen -- A Focus on Severe Acute Respiratory Syndrome (SARS) Coronavirus (SARS-CoVs) 1 and 2 / Rolando Cannalire, Enzo Tramontano, Vincenzo Summa

Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic.

New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses.